ORKA Stock Summary and Trading Ideas (Oruka Therapeutics | NASDAQ:ORKA)

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Oruka Therapeutics trades on the NASDAQ stock market under the symbol ORKA.

As of November 13, 2026, ORKA stock price declined to $104.46 with 252,826 million shares trading.

ORKA has a beta of 0.10, meaning it tends to be less sensitive to market movements. ORKA has a correlation of 0.00 to the broad based SPY ETF.

ORKA has a market cap of $7.08 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that ORKA belongs to (by Net Assets): XBI, VTI, IWM, VB, VXF.

ORKA has outperformed the market in the last year with a price return of +269.1% while the SPY ETF gained +11.2%. However, in the short term, ORKA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.7% vs -2.3% return in SPY. But in the last 2 weeks, ORKA shares have fared better than the market returning +8.1% compared to SPY -2.2%.

ORKA support price is $100.89 and resistance is $109.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ORKA shares will trade within this expected range on the day.